



David S. Perlin, Ph.D.

Executive Director and Professor
Public Health Research Institute
New Jersey Medical School/ Rutgers Biomedical and Health
Sciences
Director, Rutgers Regional Biocontainment Laboratory (RBL)
Fellow, New York Academy of Sciences



BIOGRAPHY

Dr. David S. Perlin, PhD is Executive Director of the New Jersey Medical School's Public Health Research Institute (PHRI), a 75-year-old specialized center for global infectious diseases. He is also Director of the Rutgers Regional Biocontainment Laboratory (RBL), one of thirteen NIH-designated national centers for pathogen research, and a Professor of Microbiology, Biochemistry and Molecular Genetics. Dr. Perlin is a highly accomplished administrator and medical researcher. He helped establish PHRI as a leading translational research organization specializing in infectious diseases with an annual research budget of \$25 million and a robust patent and licensing portfolio. He also established the RBL as a major national center for the study of high priority, high-threat infectious agents.

Dr. Perlin's research emphasizes studies to diagnose and overcome drug resistant fungal and bacterial infections in high-risk patients, and he is widely regarded as a global leader in the area of antifungal drug resistance and fungal molecular diagnostics. He has published more than 225 papers and book chapters and has co-authored two books. His laboratory is supported by multiple grants from the NIH, DoD, Pharma and biopharma sectors. The NIH has continuously funded him for 30 years, and he was most recently awarded a \$26.7 million grant from the NIH to lead a Center of Excellence in Translational Research to discover novel antibiotics and against drug resistant bacterial infections. His group has developed specialized diagnostic products for hospitals, clinical labs and companion diagnostics for large Pharma.

He serves on editorial boards for prominent scientific journals and is the inaugural Editor-In-Chief for the new open access *Journal of Fungi*. He also serves on the Board of Directors of the Aaron Diamond AIDS Research Center (ADARC), and Scientific/Medical Advisory Boards for the Clinical Laboratory Standards Institute (CLSI), Pharma and biotech companies, and PinnacleCare. He is a founding member of Leading International Fungal Education (LIFE) and an advisor to the new Global Action Fund for Fungal Infections (GAFFI). He is a principal consultant to the Bill and Melinda Gates Foundation for evaluating vaccine-suitable biosafety level 3 facilities. Dr. Perlin's recent awards include being named a Fellow of the New York Academy of Sciences in 2005, a distinguished visiting Professor from the University of Manchester, UK in 2009 and the Foundation Lecturer at the 2015 meeting of the British Society for Medical Mycology.

Dr. Perlin lectures on the global impact of infectious diseases and regularly comments in mainstream media outlets, such as the New York Times and NPR. He earned an AB degree from Brandeis University in 1976 and a Ph.D. from Cornell University in 1980. He pursued postdoctoral studies at the Yale University School of Medicine and the University of Rochester School of Medicine and Dentistry. Dr. Perlin joined PHRI in 1985; he was named Scientific Director in 1992, President in 2005, and Director of the new NJMS-UMDNJ (Rutgers) PHRI Center in 2006. He was appointed Professor of Microbiology and Molecular Genetics in 2003 and Executive Director of PHRI and the Rutgers Regional Biocontainment Laboratory in 2010.



PUBLIC HEALTH RESEARCH INSTITUTE

Rutgers-New Jersey Medical School
At the International Center for Public Health
225 WARREN STREET, NEWARK, NJ 07103



PHRI: SEVEN DECADES OF RESEARCH EXCELLENCE